Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasugrel for Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
NCT01794000Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of prasugrel in sickle cell disease (SCD), sponsored by Eli Lilly and Company. Started Apr 2013; status: terminated.
02
Drugs
prasugrel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01794000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01794000.